Standards & Guidelines
Become a Member
Events & Webinars
Synthetic Biology/Bioengineering – A New Route to Drug Discovery & Delivery
Insights professionals will find themselves called upon to explain therapies, devices and delivery systems developed by this novel process to providers, payers and consumers and assess responses. Client-side members need to be aware of the drug, diagnostic and delivery techniques being used in your company and competitors. Agency side members...
World Population Due to Peak – New Population Issues Emerge
Less people to feed and less patients to treat is the medium-term outlook for developed world, per the latest United Nations World Population Prospects Report. As we think about the implications for world healthcare, the issue becomes not how many people do we have but where are they moving to and how old are they? Read full report...
Healthcare Provider Roles & Autonomy in Flux: Intellus Trends Survey Wave 3 Take Aways
Summary of key take aways from wave 3 of the annual Intellus Worldwide Trends & Future survey and impacts on health insights & analytics, including: 1. How is patient site of care choice impacting primary care? 2. How are payers and systems influencing practitioners? 3. What are the implications for healthcare market research...
Centering DEI in Biopharma Market Insights
In this second thought piece, we focus on detailing potential solutions to address the underrepresentation of diverse voices and how to center diversity, equity, and inclusion (DEI) within biopharma market research. In this paper, we describe the elements of diversity worth considering in any insights work, as well as practical considerations...
Call to Action: Diversity and Inclusion in Biopharmaceutical Market Research
Intellus has teamed with representatives across biopharmaceutical companies, insights consulting firms, and fieldwork agencies to address gaps in the industry and how to bring greater diversity, equity and inclusion to healthcare insights and analytics. In this first thought piece, we detail what has been missing from biopharma market research...
Load next 5 article(s) (7 left)